GBT Pharma’s UK sister company – Precision Healthcare – has secured a commercialisation deal with Swiss-based Creso Pharma (CPH) to launch the cannaQIX range in the UK.
The nutraceutical products – cannaQIX 10 and 50 – are a proprietary formulation of full plant organic hemp extract with cannabidiol (CBD), vitamins and zinc.
Developed as a cognitive booster, cannaQIX helps to maintain mental and nervous function, reduce fatigue and release energy. Its standardised formulation offers a novel delivery system with precise dosage control, enabling a consistent, stable effect over several days. The product is safe, well-tolerated, non-euphoric, non-addictive and sugar-free.
CannaQIX is the latest addition to Precision Healthcare’s OTC consumer healthcare portfolio. The UK-based, privately-held company was founded in 2014 to support GBT Pharma’s offering in Europe. Covering more than 5000 points of sale in the UK, Precision Healthcare specialises in developing OTC consumer healthcare brands for independent pharmacy, health food channels and key accounts.
The deal will see Precision Healthcare execute the non-exclusive marketing and distribution of cannaQIX 10 and 50 across pharmacy and health food channels from spring 2018.
CPH CEO and co-founder, Dr Miri Halperin Wernli comments: “We are delighted to partner with Precision Healthcare and to have obtained the necessary regulatory approvals for cannaQIX in the UK, both significant milestones for our company.”
Matthew Caldwell-Nichols, CEO of Precision Healthcare added: “We are proud to be working with Creso Pharma in marketing this innovative range of cannabidiol and hemp-based nutraceuticals. We look forward to a successful business partnership as we grow the brand in the UK.”
To find out more about the cannaQIX range click here.
Companies interested in finding out more about cannaQIX and other Precision Healthcare brands are invited to contact us.